Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says
Executive Summary
Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels
You may also be interested in...
Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor
Merck/Schering-Plough's cholesterol-lowering agent Vytorin will carry a wholesale acquisition cost that is a 22% discount to the three highest doses of Pfizer's Lipitor
Merck/Schering’s Vytorin Clears FDA: Price Is 22% Discount To Lipitor
Merck/Schering-Plough's cholesterol-lowering agent Vytorin will carry a wholesale acquisition cost that is a 22% discount to the three highest doses of Pfizer's Lipitor
Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines
Revised cholesterol treatment guidelines could result in increased use of combination lipid-lowering therapies as Merck/Schering-Plough's Vytorin enters the market